OnCo
peoplePerson

David Cameron

David Cameron is a breast oncologist who chairs the Breast International Group.

David Cameron leads oncology research at Edinburgh and chairs BIG, the network behind HERA, APHINITY, and OlympiA; he was a senior investigator on HERA's long-term follow-up.

Role
Professor of Oncology, University of Edinburgh; Chair, Breast International Group
Specialisms
Breast cancerAdjuvant trialsTrial governance
Profiles

Key papers

1top
rctNew England Journal of Medicine 2022changed practice
DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group

Patients whose breast cancer was previously called HER2-negative may now be eligible for an effective HER2-directed drug if their tumour has even low-level HER2 staining, so pathology reports must now distinguish HER2-low (1+ or 2+/ISH-negative) from HER2-zero. This applies to metastatic disease after at least one line of chemotherapy; it does not mean these patients benefit from trastuzumab or other older HER2 drugs.

Connected

6top

cancers

1
HER2-positive breast cancer

institutions

2
Breast International Group (BIG)Edinburgh Cancer Centre / CRUK Scotland Centre

trials

2
APHINITYHERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)

key papers

1
DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group